Sangeeta N. Bhatia - 02 Jun 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
02 Jun 2021
Net transactions value
-$117,216
Form type
4
Filing time
04 Jun 2021, 16:03:09 UTC
Next filing
12 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $59,554 -285 -5% $208.96 5,465 02 Jun 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale $32,132 -153 -2.8% $210.01 5,312 02 Jun 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale $25,531 -121 -2.3% $211.00 5,191 02 Jun 2021 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $208.96 (range $208.64 to $209.48).
F3 Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $210.01 (range $209.64 to $210.34).
F5 Open market sales reported on this line occurred at a weighted average price of $211.00 (range $210.70 to $211.50).